RESUMO
With the subsisting restrictions on the use of antibiotics in poultry production, the use of plant extracts has shown some promising antimicrobial capacity similar to antibiotics; however, such capacity is largely dependent on their total polyphenol concentration and profile. Given the emerging antimicrobial potential of red osier dogwood (ROD) extract, the study aimed to investigate the pharmacodynamic effect of ROD extract on the ileal and cecal microbiota of broiler chickens challenged orally with Salmonella Enteritidis (SE). A 21 d 4 × 2 factorial experiment was conducted based on 2 main factors, including diets and SE challenge. A total of 384 one-day-old mixed-sex Cobb-500 broiler chicks were randomly allotted to 4 dietary treatments; Negative control (NC), NC + 0.075 mg trimethoprim-sulfadiazine (TMP/SDZ)/kg of diet, and NC containing either 0.3 or 0.5% ROD extract. On d 1, half of the birds were orally challenged with 0.5 mL of phosphate-buffered saline (Noninfected group) and the remaining half with 0.5 mL of 3.1 × 105 CFU/mL SE (Infected group). Dietary treatments were randomly assigned to 8 replicate cages at 6 birds/cage. On d 21, 10 birds/treatment were euthanized and eviscerated to collect ileal and cecal digesta for gut microbiota analysis. The ileal and cecal microbiota was dominated by phyla Firmicutes, Proteobacteria, and Actinobacteriota. The SE infection decreased (P < 0.05) the relative abundance of Proteobacteria and Actinobacteriota in the ileum and ceca, respectively, however, it increased (P < 0.05) Proteobacteria in the ceca. Both 0.3 and 0.5% ROD extracts (P < 0.05) depressed the relative abundance of Actinobacteriota in the ileum but marginally improved (P < 0.05) it in the ceca compared to the TMP/SDZ treatment. Dietary TMP/SDZ increased (P < 0.05) genus Bifidobacterium at the ileal and cecal segments compared to other treatments. Dietary 0.3 and 0.5% marginally improved (P < 0.05) Bifidobacterium in the ceca and depressed (P < 0.05) Weissella and was comparably similar to TMP/SDZ in the ileum. Regardless of the dietary treatments and SE infection, alpha diversity differed (P < 0.05) between ileal and cecal microbiota. Beta diversity was distinct (P < 0.05) in both ileal and cecal digesta along the SE infection model. Conclusively, both ROD extract levels yielded a pharmacodynamic effect similar to antibiotics on ileal and cecal microbiota.
Assuntos
Microbioma Gastrointestinal , Extratos Vegetais , Sulfadiazina , Trimetoprima , Animais , Antibacterianos/farmacologia , Ceco/efeitos dos fármacos , Ceco/microbiologia , Galinhas/microbiologia , Cornus , Dieta/veterinária , Íleo/efeitos dos fármacos , Íleo/microbiologia , Salmonella enteritidis/efeitos dos fármacos , Sulfadiazina/farmacologia , Trimetoprima/farmacologia , Extratos Vegetais/farmacologia , Combinação de Medicamentos , Microbioma Gastrointestinal/efeitos dos fármacos , Masculino , FemininoRESUMO
Some antimalarial drugs that have lost clinical usefulness have been repurposed for experimental applications. One example is sulfadiazine, an analog of p-aminobenzoic acid (pABA), which inhibits the parasite's folate synthesis pathway to block DNA synthesis. Sulfadiazine treatment of mice infected with Plasmodium yoelii and P. berghei is routinely used to enrich for gametocytes by killing asexual blood-stage parasites, but it is not well known if there are downstream effects on transmission. To determine if there was a significant effect of sulfadiazine exposure upon transmission, we transmitted Plasmodium yoelii (17XNL strain) parasites to Anopheles stephensi mosquitoes and evaluated the prevalence and intensity of infection under different sulfadiazine treatment conditions. We observed that there was a reduction in both the number of mosquitoes that became infected and in the intensity of infection if parasites were exposed to sulfadiazine in the mouse host or mosquito vector. Sulfadiazine treatment could be marginally overcome if mosquitoes were provided fresh pABA. In contrast, we determined that gametocytes exposed to sulfadiazine could develop into morphologically mature ookinetes in vitro, thus sulfadiazine exposure in the host may be reversible if the drug is washed out and the parasites are supplemented with pABA in the culture media. Overall, this indicates that sulfadiazine dampens host-to-vector transmission and that this inhibition can only be partially overcome by exposure to fresh pABA in vivo and in vitro. Because gametocytes are of great interest for developing transmission-blocking interventions, we recommend the use of less disruptive approaches for gametocyte enrichment. IMPORTANCE In this work, we have uncovered a substantial problem with how many studies of the sexual stages of rodent malaria parasites are conducted. Briefly, the isolation of sexual blood-stage Plasmodium parasites, or gametocytes, is essential to study pretransmission and transmission-stage biology of malaria. A routine method for the isolation of this specific stage in rodent-infectious malaria models is drug treatment with sulfadiazine, an antifolate that selectively kills actively replicating asexual blood-stage parasites but not gametocytes. Thus, researchers use this as a convenient way to produce highly enriched gametocyte samples. However, in this work, we describe how this standard drug selection with sulfadiazine not only kills asexual blood-stage parasites but also substantially impacts host-to-vector transmission.
Assuntos
Anopheles , Malária , Plasmodium yoelii , Ácido 4-Aminobenzoico , Animais , Anopheles/parasitologia , Malária/parasitologia , Camundongos , Sulfadiazina/farmacologia , Sulfadiazina/uso terapêuticoRESUMO
Delayed healing or non-healing of wounds caused by bacterial infection is still a difficult medical problem. Nowadays, the topical application of antibiotics is a common treatment for infections. However, subinhibitory concentrations or high dose of antibiotics leads to the antibacterial effect counterproductive. So it's necessary to put forward an on-demand drug delivery to solve this tough issue. In this paper, a pH-responsive hydrogel was prepared by oxidized dextran (Dex-CHO), sulfadiazine (SD) and tobramycin (TOB). The hydrogel was designed by the environment in the early immature stage of biofilm (pH 5.0). Schiff bases can release drugs in slightly acidic environment. The hydrogel showed injectable, pH-sensitive drug release, and great biocompatibility. Released SD and TOB exhibited a synergistic effect therefore the hydrogel showed high antibacterial activity. This study provides an easy and promising strategy to develop smart hydrogels that aim at topical administration of antibiotics and come up with a new treatment of local bacterial infections.
Assuntos
Antibacterianos/administração & dosagem , Infecções Bacterianas/tratamento farmacológico , Dextranos , Sistemas de Liberação de Medicamentos , Hidrogéis/química , Animais , Antibacterianos/farmacologia , Antibacterianos/uso terapêutico , Liberação Controlada de Fármacos , Escherichia coli/efeitos dos fármacos , Feminino , Concentração de Íons de Hidrogênio , Camundongos , Pseudomonas aeruginosa/efeitos dos fármacos , Staphylococcus aureus/efeitos dos fármacos , Sulfadiazina/administração & dosagem , Sulfadiazina/farmacologia , Sulfadiazina/uso terapêutico , Tobramicina/administração & dosagem , Tobramicina/farmacologia , Tobramicina/uso terapêuticoRESUMO
Antiseptics are chemical substances that when applied topically onto intact skin, mucous membranes or wounds partially or completely reduces the population of living microorganisms in those tissues. Different types of antiseptics are available - those most commonly used in clinical practice being alcohols, iodinated compounds and chlorhexidine. When using an antiseptic, consideration is required of its spectrum of antimicrobial activity, latency, residual effects, possible interferences of the presence of organic material with the activity of the antiseptic, its side effects, compatibility with other antiseptics, and cost. This article is part of a supplement entitled "Antisepsis in the critical patient", which is sponsored by Becton Dickinson.
Assuntos
Álcoois/farmacologia , Anti-Infecciosos Locais/farmacologia , Compostos de Iodo/farmacologia , Álcoois/efeitos adversos , Anti-Infecciosos Locais/efeitos adversos , Anti-Infecciosos Locais/classificação , Cátions/efeitos adversos , Cátions/farmacologia , Clorexidina/efeitos adversos , Clorexidina/farmacologia , Interações Medicamentosas , Etanol/efeitos adversos , Etanol/farmacologia , Humanos , Peróxido de Hidrogênio/efeitos adversos , Peróxido de Hidrogênio/uso terapêutico , Unidades de Terapia Intensiva , Iodo/efeitos adversos , Iodo/farmacologia , Compostos de Iodo/efeitos adversos , Iodóforos/efeitos adversos , Iodóforos/farmacologia , Compostos de Mercúrio/farmacologia , Propranolol/efeitos adversos , Propranolol/farmacologia , Sulfadiazina/efeitos adversos , Sulfadiazina/farmacologia , Triclosan/efeitos adversos , Triclosan/farmacologiaRESUMO
The recent emergence of colistin (COL) resistance, particularly mcr-1 plasmid-mediated COL resistance in Gram-negative bacteria, has led to renewed interest in antibiotic combinations to overcome clinical therapeutic impasses. The aim of this study was to evaluate the potential of the synergistic and bactericidal activity of COL in combination with sulphonamide compounds, including sulfadiazine (SDI), sulfamethoxazole (SMX) and trimethoprim/sulfamethoxazole (SXT), as well as trimethoprim (TMP) against clinical COL-resistant bacterial strains, including strains with the plasmid-encoded mcr-1 gene. A collection of 55 COL-resistant and -susceptible strains from different origins (Laos, Thailand and France) was used in this study. Several in vitro methods were used to determine the potential of the synergistic activity of these combinations, including Etest on agar pre-treated plates, the Etest cross method and the chequerboard assay. A time-kill assay was performed to evaluate the potential bactericidal activity of combinations in addition to synergistic activity. Significant synergistic activity was observed with all combinations tested. The combination of COL + SDI presented the highest synergistic effect against the various species of COL-resistant strains (92.7%). For the other combinations, a synergistic effect was also observed but with lower frequency for COL + SMX (33.3%), COL + TMP (47.3%) and COL + SXT (31.5%). Synergy was observed independently of the COL resistance mechanism. These in vitro results suggest that the combination of COL + SDI would appear to be justifiable in patients with multidrug-resistant bacterial infections that cannot be treated with COL monotherapy.
Assuntos
Antibacterianos/farmacologia , Colistina/farmacologia , Farmacorresistência Bacteriana Múltipla/efeitos dos fármacos , Bactérias Gram-Negativas/efeitos dos fármacos , Sulfadiazina/farmacologia , Sinergismo Farmacológico , Escherichia coli/efeitos dos fármacos , Proteínas de Escherichia coli/genética , França , Bactérias Gram-Negativas/genética , Humanos , Laos , Testes de Sensibilidade Microbiana , Tailândia , Trimetoprima/farmacologia , Combinação Trimetoprima e Sulfametoxazol/farmacologiaRESUMO
In the Horn of Africa, there is a high prevalence of tuberculosis that is reported to be partly driven by multidrug-resistant (MDR) Mycobacterium tuberculosis strictu sensu strains. We conducted a prospective study to investigate M. tuberculosis complex species causing tuberculosis in Djibouti, and their in vitro susceptibility to standard anti-tuberculous antibiotics in addition to clofazimine, minocycline, chloramphenicol and sulfadiazine. Among the 118 mycobacteria isolates from 118 successive patients with suspected pulmonary tuberculosis, 111 strains of M. tuberculosis, five Mycobacterium canettii, one 'Mycobacterium simulans' and one Mycobacterium kansasii were identified. Drug-susceptibility tests performed on the first 78 isolates yielded nine MDR M. tuberculosis isolates. All isolates were fully susceptible to clofazimine, minocycline and chloramphenicol, and 75 of 78 isolates were susceptible to sulfadiazine. In the Horn of Africa, patients with confirmed pulmonary tuberculosis caused by an in vitro susceptible strain may benefit from anti-leprosy drugs, sulfamides and phenicol antibiotics.
Assuntos
Antituberculosos/uso terapêutico , Mycobacterium kansasii/efeitos dos fármacos , Mycobacterium tuberculosis/efeitos dos fármacos , Tuberculose Resistente a Múltiplos Medicamentos/tratamento farmacológico , Tuberculose Pulmonar/tratamento farmacológico , Adulto , Cloranfenicol/farmacologia , Clofazimina/farmacologia , Djibuti , Feminino , Humanos , Masculino , Testes de Sensibilidade Microbiana , Pessoa de Meia-Idade , Minociclina/farmacologia , Mycobacterium kansasii/isolamento & purificação , Mycobacterium tuberculosis/classificação , Mycobacterium tuberculosis/isolamento & purificação , Estudos Prospectivos , Sulfadiazina/farmacologia , Tuberculose Resistente a Múltiplos Medicamentos/microbiologia , Tuberculose Pulmonar/microbiologiaRESUMO
Infection by Toxoplasma gondii affects around one-third of world population and the treatment for patients presenting toxoplasmosis clinically manifested disease is mainly based by a combination of sulfadiazine, pyrimethamine, and folinic acid. However, this therapeutic protocol is significantly toxic, causing relevant dose-related bone marrow damage. Thus, it is necessary to improve new approaches to investigate the usefulness of more effective and non-toxic agents for treatment of patients with toxoplasmosis. It has been described that lectins from plants can control parasite infections, when used as immunological adjuvants in vaccination procedures. This type of lectins, such as ArtinM and ScLL is able to induce immunostimulatory activities, including efficient immune response against parasites. The present study aimed to evaluate the potential immunostimulatory effect of ScLL and ArtinM for treatment of T. gondii infection during acute phase, considering that there is no study in the literature accomplishing this issue. For this purpose, bone marrow-derived macrophages (BMDMs) were treated with different concentrations from each lectin to determine the maximum concentration without or with lowest cytotoxic effect. After, it was also measured the cytokine levels produced by these cells when stimulated by the selected concentrations of lectins. We found that ScLL showed high capacity to induce of pro-inflammatory cytokine production, while ArtinM was able to induce especially an anti-inflammatory cytokines production. Furthermore, both lectins were able to increase NO levels. Next, we evaluated the treatment effect of ScLL and ArtinM in C57BL/6 mice infected by ME49 strain from T. gondii. The animals were infected and treated with ScLL, ArtinM, ArtinM plus ScLL, or sulfadiazine, and the following parameters analyzed: Cytokines production, brain parasite burden and survival rates. Our results demonstrated that the ScLL or ScLL plus ArtinM treatment induced production of pro-inflammatory and anti-inflammatory cytokines, showing differential but complementary profiles. Moreover, when compared with non-treated mice, the parasite burden was significantly lower and survival rates higher in mice treated with ScLL or ScLL plus ArtinM, similarly with sulfadiazine treatment. In conclusion, the results demonstrated the suitable potential immunotherapeutic effect of ScLL and ArtinM lectins to control acute toxoplasmosis in this experimental murine model.
Assuntos
Adjuvantes Imunológicos/farmacologia , Artocarpus/química , Lectinas/farmacologia , Extratos Vegetais/farmacologia , Toxoplasma/imunologia , Toxoplasmose/tratamento farmacológico , Toxoplasmose/imunologia , Animais , Anti-Inflamatórios/farmacologia , Encéfalo/imunologia , Encéfalo/parasitologia , Citocinas/sangue , Citocinas/efeitos dos fármacos , Testes Imunológicos de Citotoxicidade , DNA Bacteriano , Modelos Animais de Doenças , Relação Dose-Resposta Imunológica , Feminino , Lectinas/administração & dosagem , Macrófagos/efeitos dos fármacos , Macrófagos/imunologia , Camundongos , Camundongos Endogâmicos C57BL , Óxido Nítrico/análise , Carga Parasitária , Vacinas Protozoárias/imunologia , Sulfadiazina/farmacologia , Análise de Sobrevida , Toxoplasma/efeitos dos fármacos , Toxoplasma/patogenicidadeRESUMO
Herbal medicines and natural herb extracts are widely used as alternative treatments for various parasitic diseases, and such extracts may also have potential to decrease the side effects of the standard regimen drugs used to treat toxoplasmosis (sulfadiazine-pyrimethamine combination). We evaluated how effective the Thai piperaceae plants Piper betle, P. nigrum and P. sarmentosum are against Toxoplasma gondii infection in vitro and in vivo. Individually, we extracted the piperaceae plants with ethanol, passed them through a rotary evaporator and then lyophilized them to obtain crude extracts for each one. The in vitro study indicated that the P. betle extract was the most effective extract at inhibiting parasite growth in HFF cells (IC50 on RH-GFP: 23.2 µg/mL, IC50 on PLK-GFP: 21.4 µg/mL). Furthermore, treatment of experimental mice with the P. betle extract for 7 days after infection with 1,000 tachyzoites of the T. gondii PLK strain increased their survival (survival rates: 100% in 400 mg/kg-treated, 83.3% in 100 mg/kg-treated, 33.3% in 25 mg/kg-treated, 33.3% in untreated mice). Furthermore, treatment with 400 mg/kg of the P. betle extract resulted in 100% mouse survival following infection with 100,000 tachyzoites. The present study shows that P. betle extract has the potential to act as a medical plant for the treatment of toxoplasmosis.
Assuntos
Piperaceae/química , Extratos Vegetais/farmacologia , Toxoplasma/efeitos dos fármacos , Toxoplasmose Animal/prevenção & controle , Animais , Antiprotozoários/farmacologia , Antiprotozoários/uso terapêutico , Células Cultivadas , Chlorocebus aethiops , Feminino , Camundongos , Camundongos Endogâmicos C57BL , Piper betle/química , Piper nigrum/química , Extratos Vegetais/uso terapêutico , Plantas Medicinais , Sulfadiazina/farmacologia , Tailândia , Toxoplasma/crescimento & desenvolvimento , Toxoplasmose Animal/patologia , Células VeroRESUMO
Staphylococcus aureus is an important human and veterinary pathogen that causes economic loss in the poultry industry. This study aimed to compare therapeutic efficacy of 4 commonly used antibiotics in poultry on S. aureus-induced arthritis in broilers. Sixty broilers, 8 weeks of age, were assigned at random into 7 groups as follows: (1) negative control (n = 5); (2) vehicle control (n = 5); (3) sulfadiazine-trimethoprim, 250 ml/1000 l drinking water (n = 10); (4) oxytetracycline 20%, 1 mg/l drinking water (n = 10); (5) florfenicol 10%, 1/1000 v/v in drinking water (n = 10); (6) enrofloxacin 10%, 1/1000 v/v in drinking water (n = 10) and (7) positive control (n = 10). Birds in group 2 were injected with 1 ml of sterile TSB medium into the right tibiotarsal joint on d 0 while other birds (except group 1) were challenged with 1 ml of 1.2 × 10(10) CFU/ml suspension of S. aureus bacteria. Antibiotic therapy was started from d 4 post challenge and continued for 5 d. At the end, birds were weighed and clinical severity of arthritis was determined. After blood collection, birds were slaughtered and tibiotarsal and hip joints were evaluated grossly. The content of inflammatory exudates of tibiotarsal joint and the degree of femoral head necrosis were recorded. Mucin clot test and histopathological evaluation were performed on right tibiotarsal joint. Serum interleukin 6 was also assayed. Sulfadiazine-trimethoprim had higher therapeutic efficiency with regard to most of the assayed criteria, whereas none of the antibiotics significantly affected femoral head necrosis and body weight. These data will help clinicians to have better antibiotic choice in field conditions.
Assuntos
Antibacterianos/uso terapêutico , Artrite/veterinária , Galinhas , Doenças das Aves Domésticas/tratamento farmacológico , Infecções Estafilocócicas/veterinária , Animais , Antibacterianos/farmacologia , Artrite/tratamento farmacológico , Artrite/microbiologia , Combinação de Medicamentos , Enrofloxacina , Feminino , Fluoroquinolonas/farmacologia , Fluoroquinolonas/uso terapêutico , Masculino , Oxitetraciclina/farmacologia , Oxitetraciclina/uso terapêutico , Doenças das Aves Domésticas/microbiologia , Infecções Estafilocócicas/complicações , Infecções Estafilocócicas/tratamento farmacológico , Infecções Estafilocócicas/microbiologia , Staphylococcus aureus/efeitos dos fármacos , Sulfadiazina/farmacologia , Sulfadiazina/uso terapêutico , Tianfenicol/análogos & derivados , Tianfenicol/farmacologia , Tianfenicol/uso terapêutico , Resultado do Tratamento , Trimetoprima/farmacologia , Trimetoprima/uso terapêuticoRESUMO
The current work was undertaken to investigate the potential effectiveness of Thymus vulgaris ethanolic extract (TVE) against Toxoplasma gondii infection in chronic experimental toxoplasmosis. To evaluate prophylactic effects, mice received 500 mg/kg TVE for 5 days before they were infected by an avirulent Me49 T. gondii strain. To investigate the therapeutic effects of the extract postinfection, daily treatment with TVE was initiated at 6 weeks postinfection and continued for 10 days. The following groups of animals were used as controls: uninfected/non-treated, infected/non-treated, and infected/treated with a combination of pyrimethamine and sulfadiazine. Brain cyst count and histopathological changes using H&E and Feulgen stains were used to evaluate the efficacy of TVE. The mean number of brain cysts was significantly decreased by 24 % in mice treated prophylactically with TVE. TVE also significantly reduced the mean number of brain cysts when administered to animals already chronically infected with T. gondii. The effect of TVE was comparable to that of treatment with a mixture of sulfadiazine and pyrimethamine (46 and 51 % reduction, respectively). Moreover, considerable amelioration of the pathological lesions in the brain and retina was observed. The results demonstrate the potential efficacy of T. vulgaris as a new natural therapeutic and prophylactic agent for use in the treatment of chronic toxoplasmosis.
Assuntos
Extratos Vegetais/farmacologia , Thymus (Planta)/química , Toxoplasma/efeitos dos fármacos , Toxoplasmose/tratamento farmacológico , Animais , Encéfalo/parasitologia , Encéfalo/patologia , Doença Crônica , Modelos Animais de Doenças , Etanol , Humanos , Masculino , Camundongos , Extratos Vegetais/isolamento & purificação , Extratos Vegetais/uso terapêutico , Folhas de Planta/química , Pirimetamina/farmacologia , Pirimetamina/uso terapêutico , Sulfadiazina/farmacologia , Sulfadiazina/uso terapêutico , Toxoplasmose/parasitologia , Toxoplasmose/patologiaRESUMO
AIM: To present the research results concerning enhanced antimicrobial and release properties of the chitosan derivative with sulfadiazine/hyaluronic acid polyelectrolyte complex (PEC) hydrogel. MATERIAL AND METHODS: The PECs have been prepared from chitosan of different molecular weight, sulfadiazine chitosan derivative and sodium hyaluronate. The complex structure was assessed by FT-IR spectroscopic method and swelling capacity was followed by weighing measurements. RESULTS: It has been establish that chitosan derivative influenced both PEC properties and swelling capacity. CONCLUSIONS: Incorporation in PEC of the sulfadiazine chitosan is a new way to combine bacteriostatic effect of chitosan with that of sulfadiazine, to control properties, antimicrobial activity in the treatment of the wound.
Assuntos
Anti-Infecciosos/farmacologia , Materiais Biocompatíveis/farmacologia , Quitosana/farmacologia , Ácido Hialurônico/farmacologia , Sulfadiazina/farmacologia , Viscossuplementos/farmacologia , Cicatrização/efeitos dos fármacos , Anti-Infecciosos/síntese química , Anti-Infecciosos/química , Bandagens , Materiais Biocompatíveis/síntese química , Materiais Biocompatíveis/química , Quitosana/síntese química , Quitosana/química , Quimioterapia Combinada/métodos , Eletrólitos/química , Ácido Hialurônico/síntese química , Ácido Hialurônico/química , Espectrofotometria Infravermelho/métodos , Sulfadiazina/síntese química , Sulfadiazina/química , Viscossuplementos/síntese química , Viscossuplementos/químicaRESUMO
Cataract surgery, while the most common surgical procedure performed, leads to posterior capsule opacification in approximately 30% of cases. Transforming growth factor beta 2 (TGF-ß2) and matrix metalloproteinases (MMPs) have been shown to play important roles in the cellular processes leading to posterior capsule opacification. Delivery of inhibitors to MMPs may have the potential to inhibit the initial cascade of events that lead to PCO. However, delivery of these molecules via tethering has proven difficult. In this work, sulfadiazine was tethered to polydimethylsiloxane (PDMS) via a polyethylene glycol (PEG) spacer as a potential MMPI mimic. Surface characterization using a variety of methods demonstrated successful modification with the antibiotic. The surfaces were examined with lens epithelial cells to determine their effect on these cellular processes, including cell transdifferentiation and production of extracellular matrix components. The presence of TGF-ß2 in the cell culture media was found to stimulate the production of ECM components such as collagen, fibronectin, and laminin, as well as alpha smooth muscle actin (α-SMA), and the migration marker Rho by HLE-B3 and FHL124 cells. In all cases, these effects were decreased but not completely eradicated by the presence of sulfadiazine on the PDMS surfaces. While the level of inhibition necessary for inhibition of PCO in vivo is unknown, these results suggest that IOL surface modification with sulfadiazine has the potential to reduce cellular changes associated with PCO. Furthermore, the results demonstrate for the first time that changes consistent with inhibition of fibrosis may be elicited by surfaces modified with sulfadiazine.
Assuntos
Opacificação da Cápsula/tratamento farmacológico , Dimetilpolisiloxanos/química , Sulfadiazina/uso terapêutico , Actinas/metabolismo , Comunicação Celular/efeitos dos fármacos , Linhagem Celular , Movimento Celular/efeitos dos fármacos , Sobrevivência Celular/efeitos dos fármacos , Colágeno/metabolismo , Fibronectinas/metabolismo , Humanos , Lactente , Laminina/metabolismo , Cristalino/efeitos dos fármacos , Cristalino/patologia , Espectrometria de Massas , Espectroscopia Fotoeletrônica , Polietilenoglicóis/química , Espectroscopia de Infravermelho com Transformada de Fourier , Sulfadiazina/farmacologia , Propriedades de Superfície , Água/química , Proteínas rho de Ligação ao GTP/metabolismoRESUMO
OBJECTIVE: To investigate the molecular mechanisms underlying the treatment of inflammatory bowel disease (IBD) by Pulsatilla decoction. METHODS: 84 BALB/c mice were randomly divided into ethanol control group, model group, SASP group, Pulsatilla decoction group (further divided into low, middle and high dose group) and zVAD group (n = 12). Intragastric and celiac drug administration were used in each group respectively. The expression of NLRP3, ASC, Caspase-1, IL-18 and IL-1beta in the colons were detected by fluorescence quantitative RT-PCR, Elisa and immunohistochemistry after treatment respectively. RESULTS: Compared with the model group, SASP group, middle and high dose group could treat IBD effectively (P < 0.01), while this effect was restrained in zVAD group (P < 0.05). In the meantime, middle and high dose group could effectively raise the expression of NLRP3, ASC, Caspase-1, IL-18 and IL-1beta in the colons (P < 0.05), while this effect was also inhibited in zVAD group (P < 0.05). CONCLUSION: Pulsatilla decoction is likely to exert their therapeutic effect by activating NLRP3 inflammasome which further promote the formation of the corresponding inflammation factors such as 1L-18 and IL-1beta.
Assuntos
Proteínas de Transporte/metabolismo , Citocinas/metabolismo , Medicamentos de Ervas Chinesas/farmacologia , Doenças Inflamatórias Intestinais/tratamento farmacológico , Pulsatilla/química , Animais , Proteínas de Transporte/genética , Caspase 1/genética , Caspase 1/metabolismo , Citocinas/genética , Modelos Animais de Doenças , Medicamentos de Ervas Chinesas/uso terapêutico , Inflamassomos/metabolismo , Doenças Inflamatórias Intestinais/induzido quimicamente , Doenças Inflamatórias Intestinais/metabolismo , Interleucina-18/genética , Interleucina-18/metabolismo , Interleucina-1beta/genética , Interleucina-1beta/metabolismo , Mucosa Intestinal/metabolismo , Mucosa Intestinal/patologia , Camundongos , Camundongos Endogâmicos BALB C , Proteína 3 que Contém Domínio de Pirina da Família NLR , Fitoterapia , RNA Mensageiro/genética , RNA Mensageiro/metabolismo , Distribuição Aleatória , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Sulfadiazina/farmacologia , Sulfadiazina/uso terapêuticoRESUMO
The objective was to determine the effectiveness of various antimicrobial agents added to semen extender for inactivation of B. ovis or A. seminis in ovine semen after cryopreservation. In Experiment 1, 20 ejaculates from a crossbred ram infected with B. ovis were cryopreserved in Tris-based extenders with various antimicrobial agents: (I) control without antibiotics, (II) with penicillin and streptomycin (1000 IU/mL and 1 mg/mL, respectively), (III) lincomycin (0.15 mg/mL), (IV) sulphadiazine (0.60 mg/mL), and (V) gentamicin sulphate (0.25 mg/mL). Semen was stored in 0.25 mL straws at a final concentration of 150 × 10(6) spermatozoa/mL. After thawing (37 °C for 30 s), sperm total motility (TM), sperm morphology, integrity of sperm membranes, and bacterial growth were assessed. In Experiment 2, six B. ovis isolates were separately inoculated into aliquots of a fresh ejaculate from a B. ovis-free ram. Mock inoculated semen was processed for cryopreservation using the five extenders described above, and bacteriologically evaluated after thawing. In Experiment 3, sensitivity of A. seminis to the same antimicrobial agents was evaluated by inoculating an ejaculate from an A. seminis and B. ovis-free ram. There were no significant differences among treatments in post-thawing sperm parameters. B. ovis was isolated from 100% (20/20), 0% (0/20), 95% (19/20), 100% (20/20), and 5% (1/20) of semen samples diluted in tris-based extender of untreated (I) and treated semen samples with antimicrobial agents II, III, IV, and V, respectively. Frequencies of isolation from samples treated with antimicrobial agent II and V were significantly lower than untreated ones (P < 0.05). There were no significant differences in the profile of antimicrobial resistance of different B. ovis isolates. A. seminis had a similar sensitivity to the antimicrobial agents. We concluded that addition of a combination of penicillin and streptomycin or gentamicin alone to ram semen cryo-extenders inactivated B. ovis and A. seminis.
Assuntos
Anti-Infecciosos/farmacologia , Brucella ovis/efeitos dos fármacos , Criopreservação/veterinária , Preservação do Sêmen/veterinária , Sêmen/microbiologia , Ovinos/microbiologia , Actinobacillus seminis , Animais , Gentamicinas/farmacologia , Lincomicina/farmacologia , Masculino , Penicilinas/farmacologia , Estreptomicina/farmacologia , Sulfadiazina/farmacologiaRESUMO
Toxoplasma gondii infection during pregnancy may cause severe consequences to the embryo. Current toxoplasmosis treatment for pregnant women is based on the administration of spiramycin or a drug combination as sulphadiazine-pyrimethamine-folinic acid (SPFA) in cases of confirmed fetal infection. However, these drugs are few tolerated and present many disadvantages due to their toxic effects to the host. The aim of this study was to evaluate the effectiveness of different treatments on the vertical transmission of T. gondii, including azithromycin, Artemisia annua infusion, spiramycin and SPFA in Calomys callosus as model of congenital toxoplasmosis. C. callosus females were perorally infected with 20 cysts of T. gondii ME49 strain at the day that a vaginal plug was observed (1st day of pregnancy - dop). Treatment with azithromycin, A. annua infusion, and spiramycin started at the 4th dop, while the treatment with SPFA started at the 14th dop. Placenta and embryonic tissues were collected for morphological and immunohistochemical analyses, mouse bioassay and PCR from the 15th to 20th dop. No morphological changes were seen in the placenta and embryonic tissues from females treated with azithromycin, spiramycin and SPFA, but embryonic atrophy was observed in animals treated with A. annua infusion. Parasites were found in the placenta and fetal (brain and liver) tissues of animals treated with SPFA, A. annua infusion and spiramycin, although the number of parasites was lower than in non-treated animals. Parasites were also observed in the placenta of animals treated with azithromycin, but not in their embryos. Bioassay and PCR results confirmed the immunohistochemical data. Also, bradyzoite immunostaining was observed only in placental and fetal tissues of animals treated with SPFA. In conclusion, the treatment with azithromycin showed to be more effective, since it was capable to inhibit the vertical transmission of T. gondii in this model of congenital toxoplasmosis.
Assuntos
Azitromicina/farmacologia , Transmissão Vertical de Doenças Infecciosas/prevenção & controle , Sigmodontinae/parasitologia , Toxoplasmose Congênita/transmissão , Animais , Anticorpos/sangue , Anticorpos/imunologia , Artemisia annua/química , Azitromicina/uso terapêutico , DNA de Protozoário/análise , Quimioterapia Combinada , Embrião de Mamíferos/química , Embrião de Mamíferos/parasitologia , Feminino , Imuno-Histoquímica , Leucovorina/farmacologia , Leucovorina/uso terapêutico , Camundongos , Placenta/química , Placenta/parasitologia , Extratos Vegetais/farmacologia , Extratos Vegetais/uso terapêutico , Reação em Cadeia da Polimerase , Gravidez , Pirimetamina/farmacologia , Pirimetamina/uso terapêutico , Espiramicina/farmacologia , Espiramicina/uso terapêutico , Sulfadiazina/farmacologia , Sulfadiazina/uso terapêutico , Toxoplasma/imunologia , Toxoplasma/isolamento & purificação , Toxoplasmose Congênita/tratamento farmacológico , Toxoplasmose Congênita/parasitologiaRESUMO
Considering that the treatment for toxoplasmosis is based on drugs that show limited efficacy due to their substantial side effects, the purpose of the present study was to evaluate the effects of Artemisia annua on in vitro and in vivo Toxoplasma gondii infection. A. annua infusion was prepared from dried herb and tested in human foreskin fibroblasts (HFF) or mice that were infected with the parasite and compared with sulfadiazine treatment. For in vitro experiments, treatment was done on parasite before HFF infection or on cells previously infected with T. gondii and the inhibitory concentration (IC(50)) values for each treatment condition were determined. Viability of HFF cells in the presence of different concentrations of A. annua infusion and sulfadiazine was above 72%, even when the highest concentrations from both treatments were tested. Also, the treatment of T. gondii tachyzoites with A. annua infusion before infection in HFF cells showed a dose-response inhibitory curve that reached up to 75% of inhibition, similarly to the results observed when parasites were treated with sulfadiazine. In vivo experiments with a cystogenic T. gondii strain demonstrated an effective control of infection using A. annua infusion. In conclusion, our results indicate that A. annua infusion is useful to control T. gondii infection, due to its low toxicity and its inhibitory action directly against the parasite, resulting in a well tolerated therapeutic tool.
Assuntos
Artemisia annua/química , Fitoterapia , Extratos Vegetais/farmacologia , Toxoplasma/efeitos dos fármacos , Toxoplasmose Animal/tratamento farmacológico , Animais , Bioensaio , Sobrevivência Celular/efeitos dos fármacos , Células Cultivadas , Coccidiostáticos/farmacologia , Coccidiostáticos/uso terapêutico , Citocinas/análise , Feminino , Fibroblastos , Prepúcio do Pênis/citologia , Humanos , Imuno-Histoquímica , Macrófagos Peritoneais/química , Macrófagos Peritoneais/imunologia , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Endogâmicos C57BL , Nitritos/análise , Extratos Vegetais/uso terapêutico , Extratos Vegetais/toxicidade , Reação em Cadeia da Polimerase , Sigmodontinae , Sulfadiazina/farmacologia , Sulfadiazina/uso terapêutico , Toxoplasma/isolamento & purificaçãoRESUMO
Toxoplasma gondii is the etiologic agent of toxoplasmosis. Although the combination of sulfadiazine and pyrimethamine is used as therapy for this disease, these drugs can have serious side effects and its use is limited in pregnancy. Therefore there is a need for new anti-T. gondii drugs in the clinic. Some systems for T. gondii drug screening have been described, but these have limitations and can be difficult. In order to solve these problems, we established a system to screen drugs in vitro that involved using cell viability methods to calculate drug selectivities, which are Trypan blue, [3-(4,5-dimethylthiazol-zyl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazoliuzolium, inner salt] (MTS) method and lactate dehydrogenase (LDH) assay. These assays were simple to establish and perform. The IC(50) values calculated from the morphological assay were not significantly different from the EC(50) values calculated using the other three methods. In particular, the results of the morphological assay showed a distinct association with the MTS assay (R=0.9841). These assays could be used for a wide range of applications in the screening of new drugs and may provide an alternative to the techniques currently used to screen for candidate anti-T. gondii compounds in vitro. In this study, we also tested many compounds and identified some that had a good anti-T. gondii effect in vitro based on the MTS assay. This simple and fast system allowed us to determine which compounds to investigate further using in vivo experiments.
Assuntos
Coccidiostáticos/farmacologia , Avaliação Pré-Clínica de Medicamentos/métodos , Toxoplasma/efeitos dos fármacos , Animais , Corantes , Avaliação Pré-Clínica de Medicamentos/normas , Ensaio de Imunoadsorção Enzimática , Células HeLa , Humanos , Concentração Inibidora 50 , L-Lactato Desidrogenase/análise , Pirimetamina/farmacologia , Espiramicina/farmacologia , Sulfadiazina/farmacologia , Toxoplasma/fisiologia , Azul TripanoRESUMO
In this study, the prevalence and types of transferable antibiotic resistance plasmids in piggery manure were investigated. Samples from manure storage tanks of 15 farms in Germany were analysed, representing diverse sizes of herds, meat or piglet production. Antibiotic resistance plasmids from manure bacteria were captured in gfp-tagged rifampicin-resistant Escherichia coli and characterized. The occurrence of plasmid types was also detected in total community DNA by PCR and hybridization. A total of 228 transconjugants were captured from 15 manures using selective media supplemented with amoxicillin, sulfadiazine or tetracycline. The restriction patterns of 81 plasmids representing different antibiotic resistance patterns or different samples clustered into seven groups. Replicon probing revealed that 28 of the plasmids belonged to IncN, one to IncW, 13 to IncP-1 and 19 to the recently discovered pHHV216-like plasmids. The amoxicillin resistance gene bla-TEM was detected on 44 plasmids, and sulphonamide resistance genes sul1, sul2 and/or sul3 on 68 plasmids. Hybridization of replicon-specific sequences amplified from community DNA revealed that IncP-1 and pHHV216-like plasmids were detected in all manures, while IncN and IncW ones were less frequent. This study showed that 'field-scale' piggery manure is a reservoir of broad-host range plasmids conferring multiple antibiotic resistance genes.
Assuntos
Farmacorresistência Bacteriana/genética , Fertilizantes/microbiologia , Esterco/microbiologia , Plasmídeos/genética , Microbiologia do Solo , Amoxicilina/farmacologia , Animais , Antibacterianos/farmacologia , Conjugação Genética , DNA Bacteriano/genética , DNA Bacteriano/isolamento & purificação , Escherichia coli/efeitos dos fármacos , Escherichia coli/genética , Genes Bacterianos , Testes de Sensibilidade Microbiana , Plasmídeos/isolamento & purificação , Reação em Cadeia da Polimerase , Replicon , Mapeamento por Restrição , Sulfadiazina/farmacologia , Suínos , Tetraciclina/farmacologiaRESUMO
Association of specific antimicrobial resistance patterns with unrelated selective traits has long been implicated in the maintenance of antimicrobial resistance in a population. Previously we demonstrated that Escherichia coli strains with a specific resistance pattern (resistant to streptomycin, sulfadiazine, and tetracycline [SSuT]) have a selective advantage in dairy calf intestinal environments and in the presence of a milk supplement commonly fed to the calves. In the present study we identified the sequence of the genetic element that confers the SSuT phenotype and show that this element is present in a genetically diverse group of E. coli isolates, as assessed by macrorestriction digestion and pulsed-field gel electrophoresis. This element was also found in E. coli isolates from 18 different cattle farms in Washington State. Using in vitro competition experiments we further demonstrated that SSuT strains from 17 of 18 farms were able to outcompete pansusceptible strains. In a separate set of experiments, we were able to transfer the antimicrobial resistance phenotype by electroporation to a laboratory strain of E. coli (DH10B), making that new strain more competitive during in vitro competition with the parental DH10B strain. These data indicate that a relatively large genetic element conferring the SSuT phenotype is widely distributed in E. coli from cattle in Washington State. Furthermore, our results indicate that this element is responsible for maintenance of these traits owing to linkage to genetic traits that confer a selective advantage in the intestinal lumens of dairy calves.